Your browser doesn't support javascript.
loading
Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine.
Grassi, Tiziana; Lobreglio, Giambattista; Panico, Alessandra; Rosato, Chiara; Zizza, Antonella; Lazzari, Roberta; Chicone, Michele; Indino, Floriano; Bagordo, Francesco.
Afiliação
  • Grassi T; Department of Biological and Environmental Science and Technology, University of Salento, 73100 Lecce, Italy.
  • Lobreglio G; Clinical Pathology and Microbiology Unit, Vito Fazzi General Hospital, 73100 Lecce, Italy.
  • Panico A; Department of Biological and Environmental Science and Technology, University of Salento, 73100 Lecce, Italy.
  • Rosato C; Clinical Pathology and Microbiology Unit, Vito Fazzi General Hospital, 73100 Lecce, Italy.
  • Zizza A; Institute of Clinical Physiology, National Research Council, 73100 Lecce, Italy.
  • Lazzari R; Clinical Pathology and Microbiology Unit, Vito Fazzi General Hospital, 73100 Lecce, Italy.
  • Chicone M; Clinical Pathology and Microbiology Unit, Vito Fazzi General Hospital, 73100 Lecce, Italy.
  • Indino F; Clinical Pathology and Microbiology Unit, Vito Fazzi General Hospital, 73100 Lecce, Italy.
  • Bagordo F; Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, 70121 Bari, Italy.
Vaccines (Basel) ; 10(11)2022 Nov 17.
Article em En | MEDLINE | ID: mdl-36423043
ABSTRACT
Protection provided by COVID-19 vaccines is compromised due to waning immunity over time. This study aimed to assess the level of antibodies anti-S-RBD of SARS-CoV-2 in a cohort of healthcare workers before and, on average, one and four months after the third dose of the BNT162b2 vaccine. The determination of antibodies was carried out in serum samples using an electrochemiluminescence immunoassay (ECLIA). All 34 participants (10 males, 24 females, 19 participants <50 years old, 15 participants ≥50 years old) showed a significant antibody level increase after the booster dose. Subsequently, a significant decrease in the antibody concentration was observed, with a reduction of about 60% after 150 days from the booster. Six subjects were infected by SARS-CoV-2 after the booster and showed a significantly higher antibody concentration on average four months after the third dose compared to naïve ones. Male and female participants had a similar trend in the antibody decline, while older subjects, compared to the younger ones, had a slightly slower decrease, even if they developed a lower level of antibodies after the third dose. These findings support the importance of the booster dose and underline the need for surveillance programs to better understand the antibody kinetics and optimize vaccination strategies.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2022 Tipo de documento: Article